**Author details**

Patrizia Polverino de Laureto\*, Luana Palazzi and Laura Acquasaliente Protein Chemistry Unit, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy

\*Address all correspondence to: patrizia.polverinodelaureto@unipd.it

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**53**

*Polyphenols as Potential Therapeutic Drugs in Neurodegeneration*

Nature Reviews. Neuroscience.

[11] Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, et al. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nature Neuroscience.

[12] Ruiperez V, Darios F, Davletov B. Alpha-synuclein, lipids and Parkinson's disease. Progress in Lipid Research.

[13] Fecchio C, Palazzi L, Polverino de Laureto P. Alpha-synuclein and polyunsaturated fatty acids: Molecular basis of the interaction and implication in neurodegeneration. Molecules.

[14] Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. Journal of Geriatric Psychiatry and Neurology. 2010;**23**(4):213-227

[15] Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F,

protein gene with familial Alzheimer's disease. Nature. 1991;**349**(6311):704-706

[16] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;**261**(5123):921-923

[17] Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer's disease increase production of

42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nature Medicine. 1997;**3**(1):67-72

Fidani L, et al. Segregation of a missense mutation in the amyloid precursor

2001;**2**(7):492-501

2019;**22**(7):1099-1109

2010;**49**(4):420-428

2018;**23**(7):1531-1551

*DOI: http://dx.doi.org/10.5772/intechopen.89575*

[2] Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiological

[3] Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification

[4] Lee VM, Goedert M, Trojanowski JQ.

Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine.

comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Annals of the New York Academy of

[7] Masliah E, Miller A, Terry RD. The synaptic organization of the neocortex

in Alzheimer's disease. Medical Hypotheses. 1993;**41**(4):334-340

[8] Jankovic J. Parkinson's disease: Clinical features and diagnosis. Journal of Neurology, Neurosurgery, and Psychiatry. 2008;**79**(4):368-376

[9] Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;**388**(6645):839-840

[10] Goedert M. Alpha-synuclein and neurodegenerative diseases.

[1] Katzman R. Alzheimer's disease. The New England Journal of Medicine.

**References**

1986;**314**(15):964-973

Reviews. 2001;**81**(2):741-766

and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications. 1984;**120**(3):885-890

Neurodegenerative tauopathies. Annual Review of Neuroscience.

[5] Serrano-Pozo A, Frosch MP,

[6] Trojanowski JQ, Lee VM. "Fatal attractions" of proteins. A

Sciences. 2000;**924**:62-67

2001;**24**:1121-1159

2011;**1**(1):a006189

*Polyphenols as Potential Therapeutic Drugs in Neurodegeneration DOI: http://dx.doi.org/10.5772/intechopen.89575*
